Table 1.
Clinical trials with MDM2 inhibitors in soft-tissue tumors and other cancers.
| Compound | Clinical Study | Status |
|---|---|---|
| BI 907828 | Compare BI 907828 With Doxorubicin in People with a Type of Cancer Called Dedifferentiated Liposarcoma | Recruiting |
| Navtemadlin | Navtemadlin and Radiation Therapy in Treating Patients with Soft-Tissue Sarcoma | Active, not recruiting |
| DS-3032b | Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects with Relapsed and/or Refractory Multiple Myeloma | Terminated |
| Milademetan | Safety, Tolerability, and Pharmacokinetics of Milademetan Alone and with 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | Terminated |
| Cytarabine; Milademetan Tosylate |
Milademetan Tosylate and Low-Dose Cytarabine with or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | Completed |
| APG-115 | APG-115 in Salivary Gland Cancer Trial | Recruiting |
| ALRN-6924 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | Terminated |
| HDM201 | Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type | Recruiting |
| KRT-232 | Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | Recruiting |
| LXS196 | A Phase I Study of LXS196 in Patients with Metastatic Uveal Melanoma | Terminated |
Data from ClinicalTrials.gov. National Library of Medicine: http://www.clinicaltrials.gov (accessed on 13 April 2023).